Hopkins Biologist Saul Sharkis Dies at 72; Studied Blood Stem Cells’ Role in BMT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Saul Sharkis, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died Sept. 4. He was 72.

Sharkis was a professor of oncology at the Johns Hopkins University School of Medicine and a faculty member in the Johns Hopkins Kimmel Cancer Center for more than 40 years.

A native of New York, Sharkis earned his B.A. from Hunter College and his master’s and doctoral degrees from New York University. After completing his postdoctoral research at National Naval Medical Center in Bethesda, Maryland, he was recruited to the faculty of the Johns Hopkins University School of Medicine’s Department of Oncology.

Sharkis was among the first to isolate and study hematopoietic stem cells. His research was important to the progress of bone marrow and stem cell transplants because it helped reveal the mechanisms of engraftment. His work also uncovered the biology of stem cells, isolating and tracking a stem cell population to show that small numbers of stem cells can reconstitute bone marrow following transplant.

He also studied the plasticity of blood stem cells and developed research models to explore their capacity to develop into other cells, particularly epithelial cells in the liver, pancreas, kidney, breast and intestine. These cells line the organs and are often the site where cancers begin. His hope was that one day, stem cells could be use as cellular therapy to treat cancers.

“Saul inspired us with his dedication, invaluable knowledge and experience. He was a brilliant yet humble man, a superb scientist and a Johns Hopkins innovator,” said William Nelson, director of the Johns Hopkins Kimmel Cancer. “He will be sorely missed by countless residents, fellows and colleagues.”

He is survived by brother, Alan, and sister-in-law, Anne, as well as nieces and nephews.

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login